New Strategies to Enhance Smoking Cessation

Launched by UNIVERSITY OF CHICAGO · Dec 20, 2024

Keywords

ClinConnect Summary

This clinical trial aims to find better ways to help people quit smoking by improving how researchers communicate important information about smoking cessation medications, like varenicline. The study will focus on understanding what patients need to know to make informed decisions about quitting smoking, especially for Black and other racial or ethnic groups who may face additional challenges. Participants will watch a professionally created video that explains how varenicline works and how it compares to other treatments.

To take part in this study, participants should be between 18 and 75 years old, smoke at least 10 cigarettes a day, and not currently use any smoking cessation medications. They also need to be comfortable completing surveys and understand English. The study has two parts: the first part involves focus groups to help create educational materials, and the second part randomly assigns participants to receive either the new educational resources or standard smoking cessation support. Everyone in the study will have the option to use varenicline if they choose. The trial is not yet recruiting participants, but it aims to empower smokers with better information to help them quit successfully.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients must smoke at least 10 cigarettes/day and do not currently use a smoking cessation medication.
• • Ages 18-75.
• • Agree to complete surveys and measures within study.
• • Ability to understand English and the willingness to sign a written informed consent document.
• Exclusion Criteria:
• • Patients who are receiving any other smoking cessation medications.
• • Patients who are pregnant and/or lactating.
• • Patients with psychiatric contraindications that can prevent adherence to protocol or use of intervention tools in study. For inclusivity on trial, psychiatric contraindications and ability for patient to participate in trial will be assessed on an individual basis by study investigator.
• • Patients who have a contraindication with varenicline.